Skip to main content
HR 7188 118th Congress House Health Administrative law and regulatory procedures Civil actions and liability Congressional oversight Department of Health and Human Services Health programs administration and funding Health promotion and preventive care Organ and tissue donation and transplantation

Shandra Eisenga Human Cell and Tissue Product Safety Act

Introduced: February 1, 2024 Introduced by: Moolenaar, John R. Republican · Michigan See on congress.gov
 Everywhere this bill has been 16 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 17, 2024
Received in the Senate.
Dec 16, 2024
Motion to reconsider laid on the table Agreed to without objection.
Dec 16, 2024
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)
Dec 16, 2024
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H7167-7168)
Dec 16, 2024
DEBATE - The House proceeded with forty minutes of debate on H.R. 7188.
Dec 16, 2024
Considered under suspension of the rules. (consideration: CR H7167-7170)
Dec 16, 2024
Mr. Bucshon moved to suspend the rules and pass the bill, as amended.
Nov 22, 2024
Placed on the Union Calendar, Calendar No. 632.
Nov 22, 2024
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-766.
Sep 18, 2024
Ordered to be Reported (Amended) by the Yeas and Nays: 40 - 0.
Sep 18, 2024
Committee Consideration and Mark-up Session Held
May 16, 2024
Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 27 - 0.
May 16, 2024
Subcommittee Consideration and Mark-up Session Held
Feb 2, 2024
Referred to the Subcommittee on Health.
Feb 1, 2024
Referred to the House Committee on Energy and Commerce.
Feb 1, 2024
Introduced in House
 Plain-English summary Congressional Research Service

Shandra Eisenga Human Cell and Tissue Product Safety Act

This bill requires federal agencies to update guidance, regulations, and educational materials about transplants involving human cell and tissue products, particularly with respect to safety and eligibility standards.

Specifically, the Department of Health and Human Services must support the development of educational materials for health care providers about issues relating to organ, tissue, and eye donations; screening tests; and other aspects of donations. The Food and Drug Administration (FDA) must review current guidance on donor eligibility and, if appropriate, update it with information on how to reduce the spread of tuberculosis or sepsis in association with donations. The FDA must also publish information about its Tissue Reference Group and data about FDA inspections and registrations of human cell and tissue establishments.

The bill also establishes specific civil penalties for violations of regulations governing procedures for human cell and tissue products. The FDA must consider and recommend ways to update these regulations after a public comment period.

What's happening now December 17, 2024

Received in the Senate.

 Committees of jurisdiction 2